Evidence map›Paper›PMID 32850107›Full record

ArticleTherapeutic advances in chronic disease2020

Management of a Parkinson's disease patient with severe COVID-19 pneumonia.

Jingwen Li, Xi Long, Chunli Zhu, Ruiying Wang, Shaoping Hu, Tao Wang, Jinghong Li, Zhicheng Lin, Nian Xiong

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jingwen LiDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0002-2119-7848
Xi LongDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chunli ZhuDepartment of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
Ruiying WangDepartment of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
Shaoping HuDepartment of Radiology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
Tao WangDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1227 Jiefang Ave, Wuhan, Hubei, China.
Jinghong LiDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Zhicheng LinLaboratory of Psychiatric Neurogenomics, McLean Hospital, Harvard Medical School; Belmont, MA, USA.
Nian XiongDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1227 Jiefang Ave; President of Wuhan Red Cross Hospital, 392 Hongkong Road, Wuhan, Hubei, China Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
Union Hospital · CNWuhan Red Cross Hospital · CNHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elderly populations with underlying chronic diseases are more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and have higher mortality. Parkinson's disease (PD) is a neurodegenerative disease that occurs more often in elderly people. Currently, little is known about whether patients with PD are more susceptible to novel coronavirus disease 2019 (COVID-19) and whether the treatment of PD would affect the management of COVID-19 or vice versa. Here, we report a case of a PD patient with severe COVID-19 pneumonia in Wuhan, China. After diagnosis of COVID-19, this PD patient had worsening of motor symptoms, complicated with acute hypoxemic respiratory failure, urinary tract infection, and acute encephalopathy. In addition to treatment for COVID-19 and urinary tract infection, we adjusted anti-PD medicine by stepwise increasing of dose, resulting in better control of her mobility symptoms and non-motor symptoms.

Indexed as

clinical manifestationsmanagementneurodegenerationParkinson’s diseaseSARS-CoV-2

Identifiers

PMID32850107
PMCPMC7425259
OpenAlexW3048552251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.